

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 97-033-U1)

In the Application of:)	
Thurkauf, et al.)	Examiner: Emily B. Bernhardt
Serial No.: 10/	667,821)	Group Art Unit: 1624
Filed: Sep	otember 22, 2003)	Confirmation No.: 1016
For: 1-Phenyl-4 Benzylpiperazines: Dopamine Receptor Subtype Specific Ligands))	Tomania Ivon Toro

TRANSMITTAL LETTER

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

- 1. We are transmitting herewith the attached:
 - a) Response to the Office Action Mailed December 27, 2004; and
 - b) Return Receipt Postcard.
- 2. With respect to fees:
 - a) No fee is due.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
- 3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in a box addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on March 28, 2005. Express Mail No. EV595491195US.

Respectfully submitted,

Raafat M. Shaltout

Registration No. 45,092

PATENT

MAR 2 8 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: 97-033-U1)

In re Application of:)	
)	
Thurkauf et al.		
)	Before the Examiner:
)	Emily B. Bernhardt
Serial No.: 10/667,821)	
)	
Filed: September 22, 2003)	Art Unit: 1624
)	
For: 1-Phenyl-4-)	Conf. No.: 1016
Benzylpiperazines:		
Dopamine Receptor Subtype		
Specific Ligands)	

RESPONSE TO THE OFFICE ACTION MAILED DECEMBER 27, 2004

Mail Stop AF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Office Action mailed December 27, 2004, Applicants respectfully request the Examiner to reconsider the above-identified patent application in view of the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 19 of this paper.